Liposomes
In clinical developmentRecent clinical, regulatory, research and industry developments relating to this drug.
Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation.
Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.
Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles.
Lipid nanoparticle-mediated RNA delivery for immune cell modulation.
Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity.
Intravesical Liposomes for Ulcerative Cystitis
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Nature communications8
- Molecular therapy : the journal of the American Society of Gene Therapy2
- ACS nano1
- Biomolecules1
- British journal of cancer1
- Clinical and experimental medicine1
- Mitchell MJ3
- Bader AG2
- Kelnar K2
- Li JJ2
- Li Z2
- Martin D2
- Padilla MS2
- Palanki R2
- Abramson Cancer Center3
- Cardiovascular Institute3
- Institute for Immunology3
- Institute for Regenerative Medicine3
- University of Pennsylvania3
- Center for Fetal Research2
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Liposomes in the shared literature.
Studied across 4 of the same disease areas as Liposomes in the shared literature.
Studied across the same disease area as Liposomes in the shared literature.
Studied across the same disease area as Liposomes in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials